Ney Carter Borges: Coronary Intravascular Lithotripsy – Clinical Performance and Safety
Ney Carter Borges, Member Cardiologist of Global Physician Association at Cleveland Clinic Florida, shared a post on LinkedIn:
“Coronary Intravascular Lithotripsy (IVL): Clinical Performance and Safety
Coronary intravascular lithotripsy (IVL) is an established plaque-modification technique designed to facilitate optimal stent expansion in moderately to severely calcified coronary lesions. By delivering localized acoustic pressure waves through a low-pressure balloon system, IVL induces controlled microfractures in both superficial and deep calcium, improving vessel compliance while minimizing vascular trauma.
Clinical evidence from the Disrupt CAD I–IV trials demonstrates a procedural success rate of approximately 92%, defined by successful stent delivery with residual stenosis below target thresholds and absence of in-hospital major adverse cardiac events. In these studies, residual stenosis <50% was achieved in approximately 95% of treated lesions, reflecting effective calcium modification and favorable acute luminal gain.
Importantly, IVL is associated with a low incidence of serious complications, including a coronary perforation rate below 1%, which is substantially lower than that reported with some atherectomy-based strategies. This safety profile, combined with technical simplicity and a short learning curve, supports IVL as a valuable option for contemporary percutaneous coronary intervention in calcified coronary artery disease.”
Title: Shocking the Rock With Coronary Intravascular Lithotripsy in Contemporary Practice
Authors: Debabrata Dash, Anna Emily Bortnic
Read the Full Article on American College of Cardiology
Stay updated with Hemostasis Today.
-
Mar 6, 2026, 16:51Priya Reehal: Highlighting The Central Role of Nurses in Cardio-Oncology
-
Mar 6, 2026, 16:50Rainer Kaiser: Blinatumomab Shows Remarkable Response in Multi-Refractory ITP and APS
-
Mar 6, 2026, 16:18Laila Shalabi: Clopidogrel, Aspirin, and the Role of PPIs in Coronary Artery Disease
-
Mar 6, 2026, 16:17Paul McKenzie: The Value of Gene Therapy in Bleeding Disorders
-
Mar 6, 2026, 16:15Basma El Homasany: The ‘Little Brain’ of the Heart and Its Role in Health
-
Mar 6, 2026, 16:14Jamal Rana: Family History and Polygenic Risk for Coronary Heart Disease
-
Mar 6, 2026, 15:43Kristy Ainslie: Breaking Down the Discovery and FDA Approval of Drug Carriers
-
Mar 6, 2026, 15:18Claudio Laudani: Efficacy and Safety of Colchicine for Secondary Prevention in Coronary Artery Disease
-
Mar 6, 2026, 15:09Chris Simon: Persona PLUS Receives FDA Clearance for Patent‑Protected Plasma Apheresis